PL3411484T3 - Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego - Google Patents

Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego

Info

Publication number
PL3411484T3
PL3411484T3 PL17747935.9T PL17747935T PL3411484T3 PL 3411484 T3 PL3411484 T3 PL 3411484T3 PL 17747935 T PL17747935 T PL 17747935T PL 3411484 T3 PL3411484 T3 PL 3411484T3
Authority
PL
Poland
Prior art keywords
adenosatellite
virus
complementary
threaded
injection
Prior art date
Application number
PL17747935.9T
Other languages
English (en)
Inventor
Anthony DONSANTE
Karen Kozarsky
Nicholas Matthew Boulis
Jonathan Patrick Riley
Original Assignee
Emory University
Regenxbio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Regenxbio Inc. filed Critical Emory University
Publication of PL3411484T3 publication Critical patent/PL3411484T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL17747935.9T 2016-02-05 2017-01-25 Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego PL3411484T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662292157P 2016-02-05 2016-02-05
PCT/US2017/014914 WO2017136202A1 (en) 2016-02-05 2017-01-25 Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid

Publications (1)

Publication Number Publication Date
PL3411484T3 true PL3411484T3 (pl) 2024-02-19

Family

ID=59500060

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17747935.9T PL3411484T3 (pl) 2016-02-05 2017-01-25 Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego

Country Status (15)

Country Link
US (3) US12070510B2 (pl)
EP (2) EP4299079A3 (pl)
JP (4) JP2019504888A (pl)
AU (1) AU2017214283B2 (pl)
DK (1) DK3411484T3 (pl)
ES (1) ES2962860T3 (pl)
FI (1) FI3411484T3 (pl)
HR (1) HRP20231451T1 (pl)
HU (1) HUE064408T2 (pl)
IL (2) IL300254B2 (pl)
LT (1) LT3411484T (pl)
PL (1) PL3411484T3 (pl)
PT (1) PT3411484T (pl)
SI (1) SI3411484T1 (pl)
WO (1) WO2017136202A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
AU2017359342B2 (en) 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
CN111542549A (zh) 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
IL280198B2 (en) * 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
SG11202101819QA (en) * 2018-08-30 2021-03-30 Res Inst Nationwide Childrens Hospital Gene therapy for the treatment of galactosemia
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
IL283452B2 (en) * 2018-11-26 2026-04-01 Univ Barcelona Autonoma FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
AU2020218501B2 (en) * 2019-02-04 2026-01-29 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of CLN6 polynucleotide
EP3941530A4 (en) * 2019-03-21 2022-12-14 PTC Therapeutics, Inc. ANGELMAN SYNDROME TREATMENT VECTOR AND PROCEDURES
HRP20251506T1 (hr) 2019-04-10 2026-01-02 Prevail Therapeutics, Inc. Genska terapija za lizosomske poremećaje
JP7664848B2 (ja) 2019-04-10 2025-04-18 プリベイル セラピューティクス，インコーポレーテッド リソソーム障害のための遺伝子療法
EA202192801A1 (ru) * 2019-04-12 2022-02-24 Инкоудид Терапьютикс, Инк. Композиции и способы введения лекарственных средств
EP3953484A4 (en) * 2019-04-12 2023-04-12 University of Massachusetts Aav-mediated gene therapy for maple syrup urine disease (msud)
CN116096904A (zh) * 2019-12-31 2023-05-09 天鹅生物疗法有限公司 改进的aav-abcd1构建体和用于治疗或预防肾上腺脑白质营养不良(ald)和/或肾上腺脊髓神经病(amn)的用途
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
US20230226214A1 (en) * 2020-06-24 2023-07-20 Lycia Therapeutics, Inc. Bifunctional bridging compositions for viral transduction
EP4171658A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
WO2022119890A1 (en) * 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6110743A (en) 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
US8692332B2 (en) 2010-01-14 2014-04-08 United Microelectronics Corp. Strained-silicon transistor and method of making the same
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
ES2685611T3 (es) 2011-02-14 2018-10-10 The Children's Hospital Of Philadelphia Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
CN104704123A (zh) 2012-06-21 2015-06-10 肌肉学研究协会 基因治疗载体的广泛的基因递送
CA2880653C (en) * 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
BR112015027336A2 (pt) * 2013-05-01 2017-09-26 Genzyme Corp composições e processos para tratamento de atrofia muscular espinhal
EP3632923A1 (en) 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu

Also Published As

Publication number Publication date
JP2019504888A (ja) 2019-02-21
PT3411484T (pt) 2023-11-17
JP2024084797A (ja) 2024-06-25
WO2017136202A1 (en) 2017-08-10
EP3411484B1 (en) 2023-10-04
EP4299079A2 (en) 2024-01-03
US12070510B2 (en) 2024-08-27
US20250135041A1 (en) 2025-05-01
AU2017214283A1 (en) 2018-08-02
US20190038777A1 (en) 2019-02-07
JP2022101648A (ja) 2022-07-06
IL300254B2 (en) 2025-06-01
IL260954B1 (en) 2023-03-01
FI3411484T3 (fi) 2023-11-15
AU2017214283B2 (en) 2023-06-29
HRP20231451T1 (hr) 2024-03-01
ES2962860T3 (es) 2024-03-21
JP2025041933A (ja) 2025-03-26
HUE064408T2 (hu) 2024-03-28
US20240108761A1 (en) 2024-04-04
DK3411484T3 (da) 2023-11-20
CA3012653A1 (en) 2017-08-10
IL260954B2 (en) 2023-07-01
EP3411484A4 (en) 2019-08-07
SI3411484T1 (sl) 2023-12-29
LT3411484T (lt) 2023-11-27
IL300254B1 (en) 2025-02-01
EP4299079A3 (en) 2024-05-01
IL260954A (pl) 2018-09-20
IL300254A (en) 2023-03-01
EP3411484A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
IL269354A (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
HUE064408T2 (hu) Egyszálú vagy önkomplementer adeno-asszociált vírus 9 injekciója cerebrospinális folyadékba
PT3506909T (pt) Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
EP3689215A4 (en) REGIONAL ATTRIBUTE DETERMINATION
EP3464313A4 (en) MODIFIED NUCLEOTIDES 5 '-CYCLO-PHOSPHONATE
EP3430731A4 (en) IUGW ARCHITECTURE
EP3360554A4 (en) AGGREGATE AGAINST HEPATITIS B VIRUS
MA46180A (fr) Analogues de l'amyline
EP3433782A4 (en) INTEGRATED INTERACTIVE APPLICATION SAFETY TESTING
MA45192A (fr) Traitement d'association
EP3592232A4 (en) STEERABLE GUIDE CATHETER
EP3426242A4 (en) ICARIIN AND ICARITIN DERIVATIVES
MA46717A (fr) Variantes de l'endonucléase homing tcra
MA43873A (fr) Dspositif d'injection
EP3378606A4 (en) AUXILIARY SET
EP3525841A4 (en) MICRO DELIVERY DEVICE
ITUB20153015A1 (it) Dispositivo per l'infusione di fluidi
FR3055905B1 (fr) Methode de sexage precoce d'esturgeon
EP3415524A4 (en) INHIBITOR OF α-SYNNUCLEINE EXPRESSION
EP3482698A4 (en) HEMOSTATIC INSTRUMENT
EP3322451A4 (en) ELECTROCHEMICAL REDUCTION OR PREVENTING INFECTIONS
EP3431808A4 (en) BUFFER STOPPER
EP3365793A4 (en) AUTHORIZING I / O COMMANDS WITH I / O TOKENS
EP3444345A4 (en) MicroRNA-143 DERIVATIVE
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1